Jardiance Cost in North Carolina 2026: Prices, Insurance, Medicaid and Compounded Options

What Is Jardiance and Why Does the Price Matter in North Carolina

Jardiance is the brand name for empagliflozin, an SGLT2 inhibitor approved by the FDA for type 2 diabetes, heart failure with reduced and preserved ejection fraction, and chronic kidney disease (CKD) [1]. At a list price of approximately $680 per month, it sits at the upper tier of oral diabetes and cardioprotective agents. North Carolina has roughly 1.1 million adults living with diagnosed diabetes according to CDC surveillance data, making empagliflozin one of the most frequently discussed medications across the state's primary care and cardiology practices [2].

The drug's clinical weight goes beyond blood sugar. EMPA-REG OUTCOME (N=7,020), published in the New England Journal of Medicine in 2015, demonstrated that empagliflozin 10 mg or 25 mg added to standard care reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 14% (hazard ratio 0.86; 95% CI 0.74-0.99; P<0.001 for noninferiority and P=0.04 for superiority) compared with placebo [3]. Cardiovascular death specifically fell by 38%. Those numbers drove major guideline bodies to endorse empagliflozin well beyond its glucose-lowering role.

The 2023 American Diabetes Association Standards of Care recommend SGLT2 inhibitors with proven cardiovascular benefit as preferred agents for patients with established atherosclerotic cardiovascular disease, heart failure, or CKD, independent of baseline A1C [4]. That breadth of indication means more North Carolina patients are being prescribed Jardiance than ever before, and cost has become the most common barrier their clinicians report.

Jardiance List Price vs. What North Carolina Patients Actually Pay

The manufacturer list price (wholesale acquisition cost) for Jardiance in 2026 is approximately $680 per month for either the 10 mg or 25 mg tablet. That figure is the same whether you fill at a Harris Teeter pharmacy in Raleigh or a CVS in Charlotte. Cash-pay patients without any discount tool typically see a shelf price near that ceiling.

Real-world out-of-pocket costs vary considerably based on three variables: insurance tier placement, use of a savings card, and whether a prescriber switches the patient to compounded empagliflozin.

With commercial insurance: Most large group health plans in North Carolina place Jardiance on Tier 3 or Tier 4, which translates to copays of $50-$150 per 30-day supply after meeting a deductible. Some Affordable Care Act marketplace plans in NC place it on a specialty tier with coinsurance of 20-40%, meaning a patient could still owe $136-$272 per month even after their deductible is met.

With a GoodRx or similar discount coupon: Cash-pay patients can reduce the price to approximately $580-$620 per month at major NC retail chains. That is a $60-$100 reduction, meaningful but still steep.

With the Boehringer Ingelheim / Lilly Jardiance Savings Card: Commercially insured patients who meet eligibility criteria may pay as little as $10 per month. The card cannot be combined with any federal or state government insurance program, including Medicare Part D and Medicaid. Patients enroll at JardianceSavings.com or through their prescriber's office.

Without any coverage or discount tool: $680 per month is the realistic worst case for a North Carolina resident paying full cash price.

North Carolina Medicaid Coverage for Jardiance

North Carolina Medicaid covers empagliflozin for type 2 diabetes, but coverage for heart failure or CKD as standalone indications requires prior authorization and is not guaranteed. This distinction matters for the roughly 2.9 million North Carolinians enrolled in Medicaid and NC Health Choice as of late 2024 [5].

For the type 2 diabetes indication, NC Medicaid (including NC Medicaid Managed Care plans such as Healthy Blue, AmeriHealth Caritas NC, and WellCare NC) generally requires that prescribers demonstrate a clinical reason to prefer an SGLT2 inhibitor over metformin, a sulfonylurea, or another first-line agent. A prior authorization (PA) request typically includes the patient's most recent A1C, a list of contraindications to lower-cost alternatives, and, where applicable, documentation of cardiovascular or renal comorbidities.

The NC Medicaid Preferred Drug List is updated quarterly. As of the Q1 2026 cycle, Jardiance appears as a non-preferred drug for the diabetes category, meaning a step-therapy requirement typically applies before approval. Prescribers working with Medicaid patients can contact the NC Division of Medical Assistance at (919) 855-4100 to request current PA criteria or check the DMA drug coverage database at ncdhhs.gov.

For heart failure or CKD indications billed to Medicaid without a concurrent diabetes diagnosis, PA approval rates are lower and often require a specialist letter. The 2022 EMPA-KIDNEY trial (N=6,609) showed empagliflozin reduced the risk of kidney disease progression or cardiovascular death by 28% (hazard ratio 0.72; 95% CI 0.64-0.82; P<0.001) in patients with CKD, many of whom did not have type 2 diabetes [6]. That data strengthens a PA appeal but does not guarantee approval under current NC Medicaid formulary policy.

Practical tip for NC Medicaid patients: Ask your prescriber to document all relevant diagnoses (T2D plus CKD plus HF, where applicable) on the PA form. A single diagnosis of T2D with an A1C above 7.5% on metformin plus a second agent is generally the lowest-friction path to approval.

Is Compounded Empagliflozin Legal in North Carolina?

Yes. Licensed 503A compounding pharmacies in North Carolina may legally compound empagliflozin for individual patients when a prescriber issues a valid prescription and a patient-specific clinical rationale exists [7]. The key regulatory distinction is between 503A pharmacies (patient-specific, traditional compounding) and 503B outsourcing facilities (bulk, non-patient-specific). Most NC compounding pharmacies operating under the 503A model comply with USP 795 standards for non-sterile preparations.

Compounded empagliflozin is not FDA-approved, meaning the FDA has not reviewed its safety, efficacy, or manufacturing quality for the compounded form. Prescribers and patients should understand that the bioavailability of a compounded oral capsule may differ from the branded tablet, though no peer-reviewed pharmacokinetic comparison study in humans has been published as of early 2026.

The North Carolina Board of Pharmacy (ncbop.org) maintains a public license search tool where patients can verify that a pharmacy holds a current NC compounding pharmacy permit before filling. Prescriptions from telehealth providers are valid for compounded empagliflozin in NC as long as the prescriber holds a current NC medical license or a valid telehealth exemption under NC Gen. Stat. 90-18.

On cost: Some 503A compounding pharmacies in NC provide compounded empagliflozin capsules at substantially reduced prices compared with branded Jardiance. Monthly costs vary by pharmacy and dose but can be meaningfully lower than the $680 branded list price, though patients should obtain a written itemized price before agreeing to a prescription.

Which Insurance Plans Cover Jardiance in North Carolina

Coverage varies by plan type. Here is a breakdown of the major categories North Carolina residents encounter.

Employer-sponsored group plans: The majority of large group plans administered by BlueCross BlueShield of North Carolina, Aetna, Cigna, or UnitedHealthcare include Jardiance on a specialty or non-preferred brand tier. Copays range from $50 to $200 per month depending on plan design and whether the deductible has been met. Patients on high-deductible health plans (HDHPs) face full list-price exposure until the deductible clears, sometimes $1,500-$3,000 before a single prescription cent applies.

ACA Marketplace plans: NC's federal marketplace (healthcare.gov) offers Silver and Gold plans from BCBSNC and Ambetter NC. Both carriers list Jardiance on Tier 3 or Tier 4 for 2026. Silver-tier coinsurance for non-preferred brands is typically 30-40% after a combined medical and pharmacy deductible.

Medicare Part D: The Inflation Reduction Act of 2022 capped out-of-pocket drug costs for Medicare beneficiaries at $2,000 per year starting in 2025, which meaningfully reduces annual exposure for Jardiance users on Medicare [8]. Medicare patients are ineligible for the Boehringer Ingelheim / Lilly commercial savings card but may qualify for Extra Help (Low Income Subsidy) if their income falls below 150% of the federal poverty level.

Medicare Advantage (Part C): NC Medicare Advantage plans from Humana, UnitedHealthcare, and Aetna vary considerably in their formulary placement of Jardiance. Some plans include it on a preferred specialty tier with a $0-$47 copay during the initial coverage phase.

Uninsured NC residents: Without insurance and without a savings program, $680 per month is the baseline. GoodRx codes reduce this to roughly $580-$620 at Walgreens, CVS, Walmart, and Kroger-affiliated pharmacies in NC.

The Boehringer Ingelheim and Lilly Savings Card: How It Works in NC

Boehringer Ingelheim and Lilly co-market Jardiance and jointly operate the patient savings program. Commercially insured patients who are not covered by a government health plan can enroll online or at the point of dispensing. The card reduces out-of-pocket cost to as little as $10 per 30-day supply for eligible patients. There is no income verification requirement; eligibility turns entirely on insurance type.

The program covers up to $150 per fill, applied after any insurance payment. If your insurer's negotiated price after copay adjustment is $140, the card covers it entirely. If your insurer's Tier 4 copay is $250, the card covers the first $150 and you owe $100. Patients should confirm the specific benefit cap for the current plan year at JardianceSavings.com, as terms can change.

Patients receiving any benefit from Medicare Part A, Part B, Part D, Medicaid, TRICARE, or any other federal or state government program are excluded from the commercial card. This is a federal anti-kickback constraint, not a manufacturer preference. Those patients should ask their prescriber about the Boehringer Ingelheim Patient Assistance Program, which provides branded Jardiance at no cost to qualifying uninsured or underinsured patients with household incomes at or below 400% of the federal poverty level.

Telehealth Prescribing of Jardiance in North Carolina

North Carolina allows telehealth prescribing of non-controlled medications, including Jardiance and compounded empagliflozin, without a prior in-person visit, provided the prescriber establishes an appropriate patient-provider relationship through the telehealth encounter [9]. The NC Medical Board's telehealth guidance, last updated in 2023, requires that the prescribing clinician collect a sufficient medical history, perform a clinically appropriate evaluation (which may be virtual), and document the visit in a medical record.

Several telehealth platforms serving NC residents prescribe both branded Jardiance and compounded empagliflozin. The prescriber must hold a current North Carolina medical license (or applicable advanced practice nursing license under NC Gen. Stat. 90-171.20). Out-of-state clinicians working for telehealth companies must verify they meet NC licensure requirements; the NC Medical Board's IMLCC compact membership means many compact-state physicians may practice in NC under existing compact authority.

For patients considering telehealth as a route to Jardiance, the clinical workup should include a baseline metabolic panel (to confirm eGFR above 20 mL/min/1.73 m², the threshold below which empagliflozin loses glycemic efficacy), an A1C within the past 90 days, and documentation of current blood pressure and cardiovascular history. Prescribers following the 2023 ADA Standards require this baseline data regardless of visit modality [4].

Practical Steps to Lower Your Jardiance Cost in North Carolina

Getting from $680 to a manageable monthly cost takes a deliberate sequence of steps. The order matters.

Step 1: Confirm your insurance formulary placement. Call the member services number on your insurance card and ask specifically: "What tier is empagliflozin (brand name Jardiance) on my plan, and what is my copay after deductible for a 30-day supply?" Get the answer in writing via a secure message if possible.

Step 2: Apply for the savings card if commercially insured. Visit JardianceSavings.com the same day you receive your prescription. The card is activated immediately and can be presented at any retail pharmacy in NC.

Step 3: Ask about 90-day supply. Many NC pharmacies and mail-order plans offer a lower effective per-month cost on 90-day fills. A 90-day supply through a PBM mail-order pharmacy may apply only two copays for three months of medication.

Step 4: Compare compounded empagliflozin costs. If you are uninsured or your out-of-pocket remains above $150 per month after step 2, ask your prescriber whether compounded empagliflozin from a licensed NC 503A pharmacy is clinically appropriate for your situation. Confirm the pharmacy's NC Board of Pharmacy license before filling.

Step 5: Apply for patient assistance if income-eligible. The Boehringer Ingelheim Cares Foundation patient assistance program accepts applications online. Processing takes approximately 2-4 weeks. Bridging supplies may be available through your prescriber's office sample cabinet during the review period.

Step 6: File a Medicaid PA if eligible. If you are NC Medicaid-enrolled, have your prescriber submit a prior authorization request documenting your diagnosis, A1C, prior medication trials, and any cardiovascular or renal comorbidities. A cardiovascular specialist co-signature can strengthen appeals for heart failure or CKD indications.

Clinical Context: Why Empagliflozin Is Worth the Cost Conversation

The cost barrier is real, but so is the clinical cost of not treating. The EMPEROR-Reduced trial (N=3,730) showed empagliflozin 10 mg reduced the composite of cardiovascular death or hospitalization for heart failure by 25% (hazard ratio 0.75; 95% CI 0.65-0.86; P<0.001) compared with placebo over a median of 16 months [10]. The EMPEROR-Preserved trial extended that benefit to heart failure with preserved ejection fraction, a condition with very few effective pharmacologic options [11].

For patients with CKD, EMPA-KIDNEY (N=6,609) provided the most comprehensive renal data to date. The number needed to treat to prevent one kidney disease progression event or cardiovascular death over two years was 19 [6]. That is a clinically meaningful figure.

"SGLT2 inhibitors represent one of the most significant advances in cardiorenal medicine in a generation," according to a 2023 editorial in the Journal of the American Medical Association, reflecting the broad clinical consensus that has formed around this drug class [12].

The conversation about cost should happen in the exam room or the telehealth encounter, not at the pharmacy counter. Prescribers who proactively match patients to savings programs, PA pathways, or compounded alternatives before the patient leaves the visit reduce abandonment rates and keep patients on therapy long enough to realize the mortality benefit demonstrated in the trials above.